To assess DunedinPACE as a potential biomarker of disease activity in IBD, we evaluated the efficacy of both CRP and DunedinPACE in discriminating disease activity in the discovery cohort using an ROC analysis. The gene discussed is CRP; the disease is inflammatory bowel disease.